178 related articles for article (PubMed ID: 17525042)
1. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Díaz M; Miró C; Lobo F; Carrasco E; Casillas M; San Antonio B
Clin Transl Oncol; 2007 May; 9(5):317-22. PubMed ID: 17525042
[TBL] [Abstract][Full Text] [Related]
2. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Daz M; Miró C; Lobo F
Semin Oncol; 2004 Apr; 31(2 Suppl 5):31-6. PubMed ID: 15199530
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Bear HD; Tang G; Rastogi P; Geyer CE; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2015 Sep; 16(9):1037-1048. PubMed ID: 26272770
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
[TBL] [Abstract][Full Text] [Related]
5. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
[TBL] [Abstract][Full Text] [Related]
6. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Halim A; Wahba H
Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
[TBL] [Abstract][Full Text] [Related]
7. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
Artioli G; Mocellin S; Borgato L; Cappetta A; Bozza F; Zavagno G; Zovato S; Marchet A; Pastorelli D
Anticancer Res; 2010 Sep; 30(9):3817-21. PubMed ID: 20944176
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
10. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Mavroudis D; Malamos N; Polyzos A; Kouroussis Ch; Christophilakis Ch; Varthalitis I; Androulakis N; Kalbakis K; Milaki G; Georgoulias V;
Oncology; 2004; 67(3-4):250-6. PubMed ID: 15557786
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
12. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.
Gradishar WJ; Wedam SB; Jahanzeb M; Erban J; Limentani SA; Tsai KT; Olsen SR; Swain SM
Ann Oncol; 2005 Aug; 16(8):1297-304. PubMed ID: 15905305
[TBL] [Abstract][Full Text] [Related]
15. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
Antolín S; Mel R; Ramos M; García-Palomo A; Almanza C; de Paz L; Calvo L; Alvarez E; González A; García-Mata J
Clin Transl Oncol; 2011 Sep; 13(9):686-91. PubMed ID: 21865141
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Jeong JH; Jung SY; Park IH; Lee KS; Kang HS; Kim SW; Kwon Y; Kim EA; Ko KL; Nam BH; Lee S; Ro J
Invest New Drugs; 2012 Feb; 30(1):408-16. PubMed ID: 20922557
[TBL] [Abstract][Full Text] [Related]
19. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
20. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]